* DNA-based tissue typing allows for more precise HLA matching between donors and transplant patients, which has been proven to reduce the incidence and severity of<unk> D and to increase long-term survival. * The T-cells of umbilical cord blood (UCB) have an inherent immunological immaturity, and the use of UCB stem cells in unrelated donor transplants has a reduced incidence and severity of<unk> D. * Methotrexate, cyclosporin and tacrolimus are common drugs used for<unk> D prophylaxis. Further research is necessary to evaluate whether mesenchymal stromal cells can also be used for the prophylaxis. *<unk>  can largely be avoided by performing a T-cell-depleted bone marrow transplant. However, these types of transplants come at a cost of diminished<unk><unk> -tumor effect, greater risk of engraftment failure, or cancer relapse, and general immunodeficiency, resulting in a patient more susceptible to viral, bacterial, and fungal infection. In a multi-center study,<unk> -free survival at 3 years was not different between T cell-depleted and T cell-replete transplants.
Graft-versus-host disease
Transplant rejection
Cardiac allograft vasculopathy
Vasculogenic mimicry
Infectious tolerance
Disseminated disease
Chronic allograft nephropathy
Post-transplant lymphoproliferative disorder